<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918265</url>
  </required_header>
  <id_info>
    <org_study_id>tacrolimus-2</org_study_id>
    <nct_id>NCT03918265</nct_id>
  </id_info>
  <brief_title>Tacrolimus Treatment for Refractory Autoimmune Cytopenia</brief_title>
  <official_title>Tacrolimus Treatment for Refractory Autoimmune Cytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA), pure red cell aplasia&#xD;
      (PRCA), Evans syndrome (ES), usually has good responses to steroids therapies as first line,&#xD;
      but there is a considerable percentage of patients who relapse, become refractory or&#xD;
      dependent on steroids to maintain an acceptable level of hemoglobin or platelets. The effects&#xD;
      of the second line therapy are also not satisfactory and sometimes not available. The&#xD;
      investigators aim to explore the efficacy and side-effect of tacrolimus for refractory&#xD;
      autoimmune cytopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tacrolimus binds FKBP12 with high affinity after entry into cytoplasm, suppresses calcineurin&#xD;
      activity and prevents nuclear translocation of transcription factors such as NF-AT that are&#xD;
      involved in IL-2 gene transcription. As a result, T-cell activation is inhibited with a&#xD;
      subsequent reduction in the production of cytokines that include IL-2, TNF-α, IL-3, IL-4,&#xD;
      IFN-γ, IL-6 and IL-10; B-cell activation, class-switching and immunoglobulin production are&#xD;
      also attenuated. Reports on the use of tarcrolimus in the treatment of autoimmune cytopenia&#xD;
      are anecdotal and describe therapy with a variety of drug dosages.&#xD;
&#xD;
      The purpose of this study is to evaluate the effect of tacrolimus on patients with refractory&#xD;
      autoimmune cytopenia, the side-effects will be documented and plasma concentration of&#xD;
      tacrolimus will be monitor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 4, 2019</start_date>
  <completion_date type="Anticipated">November 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>6 months</time_frame>
    <description>Hemoglobin level in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet count</measure>
    <time_frame>6 months</time_frame>
    <description>Platelet count in /L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>2 years</time_frame>
    <description>Hemoglobin level in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>2 years</time_frame>
    <description>Platelet count in /L</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <condition>Pure Red Cell Aplasia</condition>
  <condition>Evans Syndrome</condition>
  <arm_group>
    <arm_group_label>Efficiency of tacrolimus on autoimmune cytopenia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A prospective research of the tacrolimus efficiency on refractory autoimmune cytopenia patients. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.&#xD;
Medication time should last at least 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study</description>
    <arm_group_label>Efficiency of tacrolimus on autoimmune cytopenia</arm_group_label>
    <other_name>tacrolimus capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractory autoimmune cytopenia, including autoimmune hemolytic anemia, pure red cell&#xD;
             aplasia, Evans syndrome.&#xD;
&#xD;
          -  18-80 years old.&#xD;
&#xD;
          -  No response or intolerant to first and second line therapies.&#xD;
&#xD;
          -  ECOG Performance Status of 0-2&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other diseases which might cause hematological abnormalities.&#xD;
&#xD;
          -  Response and well tolerate to first or second line therapy.&#xD;
&#xD;
          -  Patients who are under 18-year-old or over 80-year-old.&#xD;
&#xD;
          -  Pregnant or lactating.&#xD;
&#xD;
          -  Patients unwilling to or unable to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Hang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruoxi Zhang, M.D.</last_name>
    <phone>+86 18510064839</phone>
    <email>rx_zh15@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruoxi Zhang, MD</last_name>
      <phone>+86 18510064839</phone>
      <email>rx_zh15@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li Y, Feng X. Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study. Lupus. 2018 Jan;27(1):60-65. doi: 10.1177/0961203317711011. Epub 2017 May 31.</citation>
    <PMID>28566017</PMID>
  </reference>
  <reference>
    <citation>Tabchi S, Hanna C, Kourie HR, Aftimos P, El Osta L, Ghosn M. Successful treatment of Evans syndrome with Tacrolimus. Invest New Drugs. 2015 Feb;33(1):254-6. doi: 10.1007/s10637-014-0155-9. Epub 2014 Sep 12.</citation>
    <PMID>25209619</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Refractory autoimmune cytopenia</keyword>
  <keyword>Prospective study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Red-Cell Aplasia, Pure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

